Regulatory approval

Published by the Health Service Executive. Withdrawn

Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received 2 to 3 years of adjuvant tamoxifen.

This is written in the approval document.

Reimbursement

N/A

Citation

Anastrozole Monotherapy, 2025, version number 5, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6358/254_v5_Anastrazole.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies

Contributions

Date	Contributor	Description
2024-01-16	Van Allen lab	Adding HSE approvals for reimbursement to database
2014-11-01	Health Service Executive	Indication approved for reimbursement.